OBJECTIVES: Acromegaly is a rare slowly progressing endocrine disorder characterized by abnormally elevated levels of growth hormone (GH) and insulin-like growth factor-1 (IGF-1). Acromegaly has a significant impact on patients’ health, as well as on their physical, cognitive, emotional, and social well-being. Treatment of acromegaly is complex involving surgery, radiotherapy and medication; however, there are limited published real world data on treatment patterns. METHODS: A retrospective database analysis study using CPRD linked with Hospital Episode Statistics (HES) was conducted. Patient population included patients enrolled between January 1956 and March 2012 with Acromegaly diagnosis at two timepoints or Acromegaly diagnosis and either GH or IGF-1 test. Data was collected from 500 general practitioners (GPs). Patients’ characteristics, treatment history, comorbidities and disease control were analysed. Biochemical control was defined as an age/gender adjusted IGF-1≤ULN and GH≤2.5mg/l. Standardized Mortality Ratio (SMR) was calculated and compared to general age/gender matched UK population. RESULTS: 822 patients with Acromegaly were identified (580 alive and 242 dead at March 2012). Among alive patients, mean age (SD) was 63(15) years old, 52% male, mean age at diagnosis was 48(14).  Comorbidities included: hypertension (46%), osteoporosis (31%), arthralgia/synovitis (21%), diabetes (18%), carpal tunnel (13%) and sleep apnea (11%). 31% of patients had no treatment records. Among treated patients: 38% received TSS, 29% radiotherapy, 45% somatostatin analogs (SSAs), and 45% dopamine agonists (DAs). 45% of TSS 1st line and 52% of radiotherapy 1st line patients received further treatment. 22% of SSAs patients and 34% of DAs patients switched to/added 2nd line medical therapy. 64% of patients with GH+IGF-1 data (n=109) were not controlled.  SMR was 4.6, 3.4 and 2.5 at 5, 10 and 15 years after diagnosis respectively. CONCLUSIONS: This study demonstrated significant mortality and morbidity burden of Acromegaly in the UK GP practice.